SCHEMBL5757690

SCHEMBL5757690

OCc1ccc2c(c1)CCS2

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC5A2 P31639 2/20 0.42
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
SLC6A4 P31645 2/20 0.35
CTSL P07711 1/20 0.34
GRIN2B Q13224 2/20 0.33
CHRNB4 P30926 1/20 0.33
CHRNA3 P32297 1/20 0.33
CHRNA7 P36544 1/20 0.33
VHL P40337 1/20 0.33
ELOC Q15369 1/20 0.33
ELOB Q15370 1/20 0.33
ALDH1A1 P00352 1/20 0.32
CYP4F2 P78329 1/20 0.32
CYP4A11 Q02928 1/20 0.32
HSD17B10 Q99714 1/20 0.32
MEN1 O00255 1/20 0.31
HTT P42858 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16499627 0.89 SLC5A2 (0.44) SLC5A2LMNAMAPTCTSLGRIN2B
SCHEMBL31726624 0.89 SLC5A2 (0.44) SLC5A2LMNAMAPTCTSLGRIN2B
SCHEMBL7241941 0.85 GRIN2B (0.33) SLC5A2LMNAMAPTCTSLGRIN2B
SCHEMBL14172986 0.81 CTSL (0.46) SLC5A2LMNAMAPTSLC6A4CTSL
SCHEMBL6242819 0.80 SLC6A4 (0.38) SLC5A2LMNAMAPTSLC6A4CTSL
SCHEMBL1861656 0.79 AKR1B1 (0.50) LMNAMAPTALDH1A1HSD17B10MEN1
SCHEMBL3939490 0.78 LMNA (0.36) SLC5A2LMNAMAPTSLC6A4CTSL
SCHEMBL21383490 0.78 HSD17B10 (0.34) LMNAMAPTCTSLCHRNB4CHRNA3
SCHEMBL12894394 0.78 RYR2 (0.55)
Hydrochloric Acid SCHEMBL20562683 0.77 KDM4E (0.42) SLC5A2LMNAMAPTALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001886-A1 ENPP1 INHIBITORS I RE VENTURES I LLC (US) 2026-01-01 US disclosed
WO-2025233863-A1 ENPP1 INHIBITORS RE VENTURES I, LLC (US) 2025-11-13 WO disclosed
EP-1562902-B1 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE ASTRAZENECA AB (SE) 2006-05-03 EP disclosed
US-20060035938-A1 2-Pyridone derivatives as inhibitors of neutrophile elastase ASRAZENECA AB (SE) 2006-02-16 US disclosed
EP-1562902-A1 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE AstraZeneca AB (SE) 2005-08-17 EP disclosed
WO-2004043924-A1 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE ASTRAZENECA AB (SE) 2004-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001886-A1 ENPP1 INHIBITORS I ENPP1, ENPP2, ENPP3 SLC5A2 1509/4885LMNA 1833/4885MAPT 4345/4885
US-20060035938-A1 2-Pyridone derivatives as inhibitors of neutrophile elastase SERPINB1, ELANE, SERPINE1 SLC5A2 3151/4885LMNA 509/4885MAPT 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.